|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity显示文摘AIM: To investigate the toxicity and response of intensity-modulated radiotherapy schedule intensified with a simultaneous integrated boost in anal canal cancer.METHODS: From March 2009 to March 2014, we retrospectively analyzed 41 consecutive patients treated with intensity-modulated radiotherapy(IMRT) and concurrent chemotherapy for anal canal squamous cell carcinoma at our center. Radiotherapy was delivered via simultaneous integrated boost(SIB) technique by helical tomotherapy, and doses were adapted to two clinical target volumes according to the tumor-nodemetastasis(TNM) stage: 50.6 Gy and 41.4 Gy in 23 fractions in T1N0, 52.8 Gy and 43.2 Gy in 24 fractionsin T2N0, and 55 Gy and 45 Gy in 25 fractions in all patients with N positive and/or ≥ T3, respectively, to planning target volumes 1 and 2. The most common chemotherapy regimen was 5-fluorouracil and mitomycin-based. Human papilloma virus(HPV) p16 expression was performed by immunohistochemistry and evaluated in the majority of patients. Acute and late toxicity was scored according to CTCAe v 3.0 and RTOG scales.RESULTS: The median follow-up was 30 mo(range:12-71). Median age was 63 years(range 32-84). The stage of disease was: stage Ⅰ in 2 patients, stage Ⅱin 13 patients, stage ⅢA in 12 patients, and stage ⅢB in 14 patients, respectively. Two patients were known to be HIV positive(4.9%). HPV p16 expression status was positive in 29/34(85.3%) patients. The 4-year progression-free survival and overall survival in HPVpositive patients were 78% and 92%, respectively.Acute grade 3 skin and gastrointestinal toxicities were reported in 5% and 7.3% of patients, respectively;patients' compliance to the treatment was good due to a low occurrence of severe acute toxicity, although treatment interruptions due to toxicity were required in 7.3% of patients. At 6 mo from end of treatment,36/40(90%) patients obtained complete response;during follow-up, 5(13.8%) patients presented with disease progression(local or systemic).CONCLUSION: In our experience, intensified SIBIMRT with chemotherapy is very feasible in clinical practice, with excellent results in terms of overall survival and local control. | Liliana Belgioia Stefano Vagge Dario Agnese Stefania Garelli Roberto Murialdo Giuseppe Fornarini Silvana Chiara Fabio Gallo Almalina Bacigalupo Renzo Corvò | 2015 | World Journal of Gastroenterology2015，21，37： | 2 |
| 2 | NK cells from malignantpleural effusions are not anergic but produce cytokines and displaystrong antitumor activity on short-term IL-2 activation显示文摘 | Vacca P Martini S Garelli V | 2013 | Eur JImmunol2013，43，2： | 1 |
| 3 | Smooth sliding-mode observers for specific growth rate and suhstrate from biomass measurement显示文摘 | Pic6 J De Battista H Garelli F | 2009 | Journal of Process Control2009，19，8： | 1 |
| 4 | Incorporation of new amphiphilic perfluoroalkylated bipyridine platinum and palladium complexes into liposomes: stability and structure-incorporation relationships显示文摘 | Garelli N Vierling P | 1992 | Biochim Biophys Acta1992，1127，1： | 1 |
| 5 | The spectrum of non-classical Diamond-Blackfan anemia: a case of late beginning transfusion dependency associated to a new RP15 mutation显示文摘 | Farruggia P Quarello P Garelli E Paolicchi 0 Ruffo GB Cuccia L | 2012 | Pediatr Rep2012，4，2： | 1 |
| 6 | Sliding mode speed auto-regula- tion technique for robotic tracking 显示文摘 | Garelli F Gracia L Sala A | 2011 | Robotics and Autonomous Systems2011，59，7： | 1 |
| 7 | Cleft palate and A- DULT phenotype in a patient with a novel TP63 mutation sug- gests lumping of EEC/LM/ADULT syndromes into a unique en- tity : ELA syndrome 显示文摘 | Prontera P Garelli E Isidori I | 2011 | Am J Med Genet2011，155，11： | 1 |
| 8 | Trophic Factors and Neuronal Interactions Regulate the Cell Cycle and Pax6 Expression in Muller Stem Cells 显示文摘 | Insua MF Sim6n MV Garelli A | 2008 | J Neurosci Res2008，7，： | 1 |
| 9 | Synthesis of new amphiphilic perfluoroalkylated bipyridines 显示文摘 | GARELLI N VIERLING P | 1992 | J Org Chem1992，57，： | 1 |
| 10 | Diagnosis and classifi- cation of autoimmune parathyroid disease 显示文摘 | Bettede C Garelli S Presotto F | 2014 | Autoim- mun Rev2014，13，： | 1 |
| 11 | Auxetic compliant flexible PU foams: static and dynamic properties 显示文摘 | SCARP F PASTORINO P GARELLI A | 2005 | Physica Status Solidi: b2005，242，3： | 1 |
| 12 | Videodermoscopy Scalp Psoriasis Seberity Index(VSCAPSI):A useful tool for evaluation of scalp psoriasis显示文摘 | Rossi A Mandel VD Garelli V | 2011 | Eur J Dermatol2011，21，4： | 1 |
| 13 | High prevalence of chronic thyroiditis in patients with polycystic ovary syndrome显示文摘 | Garelli S Masiero S Plebani M | 2013 | Eur J Obstet Gynecol Reprod Biol2013，169，： | 1 |
| 14 | Sublingual immunotherapy for allergic rhinitis and conjunctivitis显示文摘 | Passalacqua G Garelli V Sclifo F | 2013 | Immunotherapy2013，5，3： | 1 |
| 15 | Sliding mode speed auto-regulation technique for robotic tracking显示文摘 | Fabricio Garelli Luis Gracia Antonio Sala | 2011 | Robotics and Autonomous Systems2011，59，78： | 1 |
| 16 | High prevalence of chronic thyroiditis in patients with polycystic ovary syndrome显示文摘 | Silvia Garelli Stefano Masiero Mario Plebani Shu Chen Jadwiga Furmaniak Decio Armanini Corrado Betterle | 2013 | European Journal of Obstetrics and Gynecology2013，，： | 1 |
| 17 | Theworldcompetitivenesslandscapein2004显示文摘 | GARELLIS | 2004 | ManagementServices2004，48，9： | 1 |
| 18 | Power conditioning for a wind-hydrogen energy system 显示文摘 | Battista H D Mantz R J Garelli F | 2006 | Journal of Pow- er Sources2006，155，2： | 1 |
| 19 | May we strengthen the hu- man natural defenses with bacterial lysates? 显示文摘 | Villa E Garelli V Braido F | 2010 | WAO J2010，3，： | 1 |
| 20 | Rapp-Hodgkin and AEC syndromes due to a new frameshift mutation in the TP63 gene 显示文摘 | Dianzani I 1 Garelli E 2 Gustavsson P 4 Carando A 2 Gustafsson B 3 Dahl N 4 Anneren G 4 | 2003 | Journal of Medical Genetics2003，40，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员